1. An aqueous dispersion of a polythiophene and at least one colloid-forming polymeric acid wherein the polythiophene has repeating units with the structure.
wherein:
R2 and R2\u2032 are independently selected so as to be the same or different at each occurrence and is selected from hydrogen, alkyl, alkenyl, alkoxy, alkanoyl, alkythio, aryloxy, alkylthioalkyl, alkylaryl, arylalkyl, amino, alkylamino, dialkylamino, aryl, alkylsulfinyl, alkoxyalkyl, alkylsulfonyl, arylthio, arylsulfinyl, alkoxycarbonyl, arylsulfonyl, acrylic acid, phosphoric acid, phosphonic acid, halogen, nitro, cyano, hydroxyl, epoxy, silane, siloxane, alcohol, benzyl, carboxylate, ether, ether carboxylate, amidosulfonate, ether sulfonate, and urethane; or both R1 groups together may form an alkylene or alkenylene chain completing a 3, 4, 5, 6, or 7-membered aromatic or alicyclic ring, which ring may optionally include one or more divalent nitrogen, sulfur or oxygen atoms; and may be substituted with one or more R3 groups;
R3 is independently selected so as to be the same or different at each occurrence and is selected from hydrogen, alkyl, alkenyl, aryl, alkanoyl, alkylthioalkyl, alkylaryl, arylalkyl, amino, epoxy, silane, siloxane, alcohol, amidosulfonate, benzyl, carboxylate, ether, ether carboxylate, ether sulfonate, and urethane.
2. The composition of claim 1, wherein said colloid-forming polymeric acid is selected from polymeric sulfonic acids, polymeric carboxylic acids, polymeric acrylic acids, and polymeric phosphoric acids.
3. The composition of claim 2, wherein said colloid-forming polymeric acid is a fluorinated polymeric sulfonic acid.
4. An organic electronic device having at least one layer comprising the composition of claim 1.
5. The device of claim 4, wherein the layer is a buffer layer.
6. The device of claim 4 wherein the device is selected from the group of an organic light omitting diode display, a photoconductive cell, a photodector, photoresistors, phototube, photoswitch, photovoltaic cell, solar cell and photo transisitor.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of the general formula (I) and salts thereof,
86
wherein
A is a non-aromatic ring system containing five carbon atoms, wherein the ring system comprises at least one double bond and wherein one or more of the carbon atoms in the ring can be replaced by a group X, wherein X is selected from the group consisting of S, O, N, NR4, SO or SO2, and wherein one or more of the carbon atoms of the ring can carry a substituent R1;
D is O, S, SO2, NR4, or CH2;
Z1 and Z2 are independent from each other O, S, or NR5;
R1 is independently H, halogen, haloalkyl, haloalkyloxy or alkyl;
R2 is H, OR6, or NHR7;
R3 is H, alkyl, cycloalkyl, aryl, arylalkyl, alkoxy, O-aryl; O-cycloalkyl, halogen, aminoalkyl, alkylamino, hydroxylamino, hydroxylalkyl, haloalkyl, haloalkyloxy, heteroaryl, alkylthio, S-aryl, or S-cycloalkyl;
R4 is H, alkyl, cycloalkyl, aryl, or heteroaryl;
R5 is H, OH, alkoxy, O-aryl, alkyl, or aryl;
R6 is H, alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, alkylaryl, alkoxyalkyl, acylmethyl, (acyloxy)alkyl, non-symmetrical (acyloxy)alkyldiester, or dialkylphosphate;
R7 is H, alkyl, aryl, alkoxy, O-aryl, cycloalkyl, or O-cycloalkyl;
R8 is hydrogen or alkyl;
E is an alkyl or cycloalkyl group or a monocyclic or polycyclic substituted or unsubstituted ring system which may contain one or more groups X and which contains at least one aromatic ring;
Y is hydrogen, halogen, haloalkyl, haloalkyloxy, alkyl, cycloalkyl, a monocyclic or polycyclic substituted or unsubstituted ring system which may contain one or more groups X and which contains at least one aromatic ring or
87
m is 0 or 1;
n is 0 or 1;
p is 0 or 1;
r is 0 or 1; and
q is 0 to 10;
with the proviso that when the ring A is an unsubstituted carbocycle containing five carbon atoms and one double bond between the CZ1 and CZ2-substituents, wherein Z1Z2O, and R2OH, and r1, the following compounds are excluded:
q0; Yhydrogen; Ephenylene or naphthylene, phenylene substituted with one or two chlorine atoms or with 2-methyl, 4-methyl, 4-methoxy, 4-ethoxy, 2,6-diethyl, 2-chloro-4-methyl,4-bromo, 4-cyano, 2,3-difluoro, 2,6-difluoro, 2,3,4-trifluoro;
q0; Yphenyl; Ephenylene;
q1; m1; n1; R3H; Ephenylene; Y4-chloro-phenyl; DO, S;
q1; m1; n1; R3H; Ephenylene; Y4-phenyl; DO.
2. A compound of the general formula (Ia) and salts thereof,
88
wherein
A is a non-aromatic ring system containing 4, 6, 7 or 8 carbon atoms, wherein the ring system comprises at least one double bond and wherein one or more of the carbon atoms in the ring can be replaced by a group X, wherein X is selected from the group consisting of S, O, N, NR4, SO or SO2, and wherein one or more of the carbon atoms of the ring can carry a substituent R1;
D is O, S, SO2, NR4, or CH2;
Z1 and Z2 are independent from each other O, S, or NR5;
R1 is independently H, halogen, haloalkyl, haloalkyloxy or alkyl;
R2 is H, or OR6;
R3 is H, alkyl, cycloalkyl, aryl, alkoxy, O-aryl; O-cycloalkyl, halogen, aminoalkyl, alkylamino, hydroxylamino, hydroxylalkyl, haloalkyloxy, heteroaryl, alkylthio, S-aryl; S-cycloalkyl, arylalkyl, or haloalkyl;
R4 is H, alkyl, cycloalkyl, aryl or heteroaryl;
R5 is H, OH, alkoxy, O-aryl, alkyl or aryl;
R6 is H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, alkylaryl, alkoxyalkyl, acylmethyl, (acyloxy)alkyl, non-symmetrical (acyloxy)alkyldiester, or dialkylphosphate;
R8 is hydrogen or alkyl;
E is an alkyl or cycloalkyl group or a monocyclic or polycyclic substituted or unsubstituted ring system which may contain one or more groups X and which contains at least one aromatic ring;
Y is a monocyclic or polycyclic substituted or unsubstituted ring system which may contain one or more groups X and which contains at least one aromatic ring or
89
m is 0 or 1;
n is 0 or 1;
p is 0 or 1;
r is 0 or 1; and
q is 0 to 10;
3. The compound of claim 1 wherein Z1 and Z2 are both O and r1.
4. The compound of claim 1, wherein r1, and E is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, 9H-thioxanthene-10,10-dioxide, or cycloalkyl.
5. The compound of claim 1, wherein Z1 and Z2 are both O, and r1, and E is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, 9H-thioxanthene-10,10-dioxide, or cycloalkyl.
6. The compound of claim 1, wherein wherein E is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, 9H-thioxanthene-10,10-dioxide, or cycloalkyl and r1, and R2 is OH or OR6.
7. The compound of claim 1, wherein wherein Z1 and Z2 are both O, and r1, and E is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, 9H-thioxanthene-10,10-dioxide, or cycloalkyl and R2 is OH or OR6.
8. The compound of claim 2, wherein Z1 and Z2 are both O and r1.
9. The compound of claim 2, wherein r1, and F is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, 9H-thioxanthene-10,10-dioxide, or cycloalkyl .
10. The compound of claim 2, wherein Z1 and Z2 are both O and r1, and E is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, 9H-thioxanthene-10,10-dioxide, or cycloalkyl.
11. The compound of claim 2, wherein wherein E is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, 9H-thioxanthene-10,10-dioxide, or cycloalkyl and r1, and R2 is OH or OR6.
12. The compound of claim 2, wherein wherein Z1 and Z2 are both O, and r1, and E is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, 9H-thioxanthene-10,10-dioxide, or cycloalkyl and R2 is OH or OR6.
13. A pharmaceutical composition comprising a compound as defined in claim 1 in free form or in the form of pharmaceutically acceptable salts and physiologically functional derivatives, together with pharmaceutically acceptable diluents or carriers.
14. A pharmaceutical composition comprising a compound as defined in claim 2 in free form or in the form of pharmaceutically acceptable salts and physiologically functional derivatives, together with pharmaceutically acceptable diluents or carriers.
15. A compound according to claim 1, including the compounds, in which the ring A is an unsubstituted carbocycle containing five carbon atoms and one double bond between the CZ1 and CZ2-substituents, wherein Z1Z2O, and r1, and R2OH:
q0; Yhydrogen; Ephenylene or naphthylene, phenylene substituted with one or two chlorine atoms or with 2-methyl, 4-methyl, 4-methoxy, 4-ethoxy, 2,6-diethyl, 2-chloro-4-methyl, 4-bromo, 4-cyano;
q0; Yphenyl; Ephenylene;
q1; m1; n1; R3H; Ephenylene; Y4-chloro-phenyl; DO, S;
q1; m1; n1; R3H; Ephenylene; Y4-phenyl; DO;
for the use as a medicament.
16. A compound according to claim 2 for the use as a medicament.
17. The use of a compound of the formula (I) as defined in claim 1, including the compounds excluded in claim 1, and physiologically functional derivatives and their pharmacologically tolerable salts in the manufacture of a medicament for use in treatment of a disease or a therapeutic indication in which inhibition of dihydrooratate dehydrogenase is beneficial.
18. The use of a compound of the formula (Ib) as defined in claim 2 and physiologically functional derivatives and their pharmacologically tolerable salts in the manufacture of a medicament for use in treatment of a disease or a therapeutic indication in which inhibition of dihydrooratate dehydrogenase is beneficial.
19. The use of claim 17 wherein the disease or indication is selected from the group consisting of rheumatism, acute immunological disorders, autoimmune diseases, diseases caused by malignant cell proliferation, inflammatory diseases, diseases that are caused by protozoal infestations in humans and animals, diseases that are caused by viral infections and Pneumocystis carinii, fibrosis, uveitis, rhinitis, asthma or athropathy.
20. The use of claim 18 wherein the disease or indication is selected from the group consisting of rheumatism, acute immunological disorders, autoimmune diseases, diseases caused by malignant cell proliferation, inflammatory diseases, diseases that are caused by protozoal infestations in humans and animals, diseases that are caused by viral infections and Pneumocystis carinii, fibrosis, uveitis, rhinitis, asthma or athropathy.
21. The use of a compound as defined in claim 1 for the inhibition of DHODH.
22. The use of a compound as defined in claim 2 for the inhibition of DHODH.
23. A process for the preparation of a compound of formula (I) which comprises the step of reacting an acid anhydrid of formula (II) with an amine of formula (III) or an amine of formula (IV) with a boronic acid of formula (V) or the step of reacting an halogen derivative of the formula (VI) with an arylboronic acid of the general formula (VII).
24. A process for the preparation of a compound of formula (Ia) which comprises the step of reacting an acid anhydrid of formula (II) with an amine of formula (III) or an amine of formula (IV) with a boronic acid of formula (Va) or the step of reacting an halogen derivative of the formula (VI) with an arylboronic acid of the general formula (VIIa).
25. A method for the treatment or prophylaxis of a condition where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH) which comprises the administration of an effective amount of a compound of formula (I) as defined in claim 1 including the compounds excluded in claim 1 and physiologically acceptable salts and physiologically functional derivatives thereof.
26. A method for the treatment or prophylaxis of a condition where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH) which comprises the administration of an effective amount of a compound of formula (Ia) as defined in claim 2 and physiologically acceptable salts and physiologically functional derivatives thereof.